

1. (Amended) A pharmaceutical composition for the prevention or treatment of soft tissue cancer in mammals, comprising, in admixture with a pharmaceutically acceptable carrier, at least one plant essential oil compound selected from the group consisting of aldehyde C16 (pure), amyl cinnamic aldehyde, amyl salicylate, anisic aldehyde, benzyl alcohol, benzyl acetate, cinnamaldehyde, cinnamic alcohol, α -terpineol, carvacrol, carveol, citral, citronellal, citronellol, p-cymene, diethyl phthalate, dimethyl salicylate, dipropylene glycol, eucalyptol (cincol), eugenol, iso-eugenol, galaxolide, geraniol, guaiacol, ionone, d-limonene, menthol, methyl anthranilate, methyl ionone, methyl salicylate, α -phellandrene, pennyroyal oil, perillaldehyde, 1- or 2-phenyl ethyl alcohol, 1- or 2-phenyl ethyl propionate, piperonal, piperonyl acetate, piperonyl alcohol, D-pulegone, terpinen-4-ol, terpinyl acetate, 4-tert butylcyclohexyl acetate, thyme oil, thymol, metabolites of trans-anethole, vanillin, and ethyl vanillin, wherein the plant essential oil has antiestrogenic activity against E_2 -induced abnormal cell growth.

2. (Amended) The pharmaceutical composition of claim 1, wherein the E_2 -induced abnormal cell growth is breast cancer.

3. (Amended) The pharmaceutical composition of claim 1, wherein the plant essential oil compound is eugenol.

4. (Amended) The pharmaceutical composition of claim 1, wherein the plant essential oil compound is thymol.

5. (Amended) The pharmaceutical composition of claim 1, wherein the plant essential oil compound is isoeugenol.

6. (Amended) The pharmaceutical composition of claim 1, wherein the plant essential oil compound is benzyl alcohol.